This inventor holds 1 USPTO granted patent. Top assignee: Merck + Co., Inc.. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: Scott Hoerrner: Innovator in Pharmaceutical Chemistry
Introduction
Scott Hoerrner is a notable inventor based in Westfield, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the synthesis of CCR-2 antagonists. His work has implications for the development of new therapeutic agents.
Latest Patents
Scott Hoerrner holds a patent for a process related to the preparation of CCR-2 antagonists. The patent details an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt. Additionally, the invention provides methods for synthesizing various intermediates and precursors, showcasing the innovative approach taken by Hoerrner in this complex chemical landscape.
Career Highlights
Scott Hoerrner is associated with Merck & Co., Inc., a leading global healthcare company. His work at Merck has allowed him to focus on the development of new pharmaceutical compounds that can potentially improve patient outcomes. His expertise in synthetic chemistry has been instrumental in advancing the company's research initiatives.
Collaborations
Scott has collaborated with talented coworkers, including Elizabeth Szumigala and Lihu Yang. These collaborations have fostered a productive environment for innovation and have contributed to the successful development of new chemical entities.
Conclusion
Scott Hoerrner's contributions to pharmaceutical chemistry, particularly through his patent on CCR-2 antagonists, highlight his role as an innovator in the field. His work at Merck & Co., Inc. and collaborations with colleagues further emphasize the importance of teamwork in driving scientific advancements.